Patent classifications
C07K16/40
ANTIGEN-BINDING CONSTRUCTS THAT BIND TO AND INHIBIT CATALASE AND/OR SUPEROXIDE DISMUTASE AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR TUMOR THERAPY
The invention relates to single domain VHH fragments which specifically bind to and inhibit superoxide dismutase and/or bind to and inhibit catalase and/or bind to and inhibit superoxide dismutase and catalase, in particular for the use in the therapy of tumor diseases.
ANTIGEN-BINDING CONSTRUCTS THAT BIND TO AND INHIBIT CATALASE AND/OR SUPEROXIDE DISMUTASE AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR TUMOR THERAPY
The invention relates to single domain VHH fragments which specifically bind to and inhibit superoxide dismutase and/or bind to and inhibit catalase and/or bind to and inhibit superoxide dismutase and catalase, in particular for the use in the therapy of tumor diseases.
BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES AND METHODS OF USE
The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.
BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES AND METHODS OF USE
The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.
ANTI-MERTK AGONISTIC ANTIBODIES AND USES THEREOF
The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.
ANTI-MERTK AGONISTIC ANTIBODIES AND USES THEREOF
The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.
SURFACE, ANCHORED FC-BAIT ANTIBODY DISPLAY SYSTEM
The present invention provides, in part, an antibody display system that simultaneously uses a secretion and a display mode. A bait complexed with a monovalent antibody fragment can be expressed on the surface of the host cell wherein the fragment may be assayed for antigen binding while full antibody is simultaneously secreted from the host cell. Methods of using the system for identifying antibodies that bind specifically to an antigen of interest are also provided. Polypeptides, polynucleotides and host cells useful for making the antibody display system are also provided along with methods of use thereof.
SURFACE, ANCHORED FC-BAIT ANTIBODY DISPLAY SYSTEM
The present invention provides, in part, an antibody display system that simultaneously uses a secretion and a display mode. A bait complexed with a monovalent antibody fragment can be expressed on the surface of the host cell wherein the fragment may be assayed for antigen binding while full antibody is simultaneously secreted from the host cell. Methods of using the system for identifying antibodies that bind specifically to an antigen of interest are also provided. Polypeptides, polynucleotides and host cells useful for making the antibody display system are also provided along with methods of use thereof.
ISOLATION OF ADULT MULTIPOTENTIAL CELLS BY TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE
The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.
ISOLATION OF ADULT MULTIPOTENTIAL CELLS BY TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE
The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.